SEC
SGMO

Seven Eight Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Seven Eight Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,800
Closed -$527K – 687
2021
Q1 		$527K Hold
33,800
– – 0.12% 256
2020
Q4 		$527K Buy
33,800
+7,645
+29% +$89.6K 0.12% 259
2020
Q3 		$247K Buy
+26,155
New +$283K 0.05% 484
2019
Q2 		– Sell
-47,000
Closed -$448K – 718
2019
Q1 		$448K Buy
+47,000
New +$480K 0.02% 454
2018
Q2 		– Sell
-63,289
Closed -$1.2M – 568
2018
Q1 		$1.2M Buy
63,289
+41,089
+185% +$878K 0.1% 219
2017
Q4 		$364K Buy
+22,200
New +$330K 0.04% 362

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Seven Eight Capital's SGMO Position: Q2 2021 in Review

Seven Eight Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2021, closing a stake of 33,800 shares — an estimated $527K sold.

Seven Eight Capital first reported a position in SGMO in Q4 2017 and held it in 6 quarters. The position peaked at $1.2M in Q1 2018. 197 funds tracked by Wall St. Rank hold SGMO as of Q2 2021.

  • Seven Eight Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2021 after selling out during the quarter.
  • Seven Eight Capital sold 33,800 SANGAMO THERAPEUTICS INC shares in Q2 2021, an estimated $527K.
  • Seven Eight Capital first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 6 quarters.
  • Seven Eight Capital's SANGAMO THERAPEUTICS INC position peaked at $1.2M in Q1 2018.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2021.

Based on Seven Eight Capital's 13F filing for Q2 2021, filed 13 Aug 2021.